Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.53 |
| ▸ | CXCR4 | P61073 | 6/20 | 0.40 |
| ▸ | CTSD | P07339 | 1/20 | 0.40 |
| ▸ | GHSR | Q92847 | 2/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.38 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.37 |
| ▸ | ITGAV | P06756 | 1/20 | 0.37 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5562472 | 1.00 | HRH3 (0.53) | HRH3CXCR4CTSDGHSRHDAC8 | |
| SCHEMBL3205012 | 0.84 | HRH3 (0.53) | HRH3CXCR4OPRM1OPRD1OPRK1 | |
| SCHEMBL21683131 | 0.84 | HRH3 (0.53) | HRH3CXCR4CTSDGHSRHDAC8 | |
| SCHEMBL21683128 | 0.84 | HRH3 (0.53) | HRH3CXCR4CTSDGHSRHDAC8 | |
| SCHEMBL12809436 | 0.84 | HRH3 (0.53) | HRH3CXCR4OPRM1OPRD1OPRK1 | |
| SCHEMBL5564861 | 0.84 | HRH3 (0.53) | HRH3CXCR4OPRM1OPRD1OPRK1 | |
| SCHEMBL12809721 | 0.84 | HRH3 (0.53) | HRH3CXCR4CTSDGHSRHDAC8 | |
| SCHEMBL1598687 | 0.83 | HDAC8 (0.57) | HRH3CXCR4CTSDGHSRHDAC8 | |
| SCHEMBL1673516 | 0.83 | HDAC8 (0.57) | HRH3CXCR4CTSDGHSRHDAC8 | |
| SCHEMBL7304234 | 0.83 | HDAC8 (0.57) | HRH3CXCR4CTSDGHSRHDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1492794-B1 | PIPERAZINE SUBSTITUTED ARYL BENZODIAZEPINES AND THEIR USE AS DOPAMINE RECEPTOR ANTAGONISTS FOR THE TREATMENT OF PSYCHOTIC DISORDERS | LILLY CO ELI (US) | 2007-12-12 | — | — | EP | disclosed |
| US-7214673-B2 | For therapy of psychosis and bipolar disorder | ELI LILLY AND COMPANY (US) | 2007-05-08 | — | — | US | disclosed |
| US-20050203296-A1 | For therapy of psychosis and bipolar disorder | ELI LILLY AND COMPANY | 2005-09-15 | — | — | US | disclosed |
| EP-1492794-A1 | PIPERAZINE SUBSTITUTED ARYL BENZODIAZEPINES AND THEIR USE AS DOPAMINE RECEPTOR ANTAGONISTS FOR THE TREATMENT OF PSYCHOTIC DISORDERS | ELI LILLY AND COMPANY (US) | 2005-01-05 | — | — | EP | disclosed |
| WO-2003082877-A1 | PIPERAZINE SUBSTITUTED ARYL BENZODIAZEPINES AND THEIR USE AS DOPAMINE RECEPTOR ANTAGONISTS FOR THE TREATMENT OF PSYCHOTIC DISORDERS | ELI LILLY AND COMPANY (US) | 2003-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050203296-A1 | For therapy of psychosis and bipolar disorder | DRD4, AFF4, DRD2 | HRH3 65/4885CXCR4 1055/4885CTSD 4215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.